Dysbiosis of the Gut Microbiome in Polycystic Ovary Syndrome
Overview
Polycystic ovary syndrome (PCOS) is linked to gut microbiome dysbiosis, which influences its pathogenesis through metabolic, immune, and endocrine pathways. Targeted interventions such as dietary changes, probiotics, and fecal microbiota transplantation show promise as novel treatments.
Background
PCOS is a prevalent endocrine disorder characterized by hyperandrogenemia, ovulatory dysfunction, and insulin resistance, often accompanied by chronic inflammation. These disturbances increase risks for diabetes, cardiovascular disease, and infertility. The gut microbiome plays a crucial role in metabolic and hormonal regulation, and its imbalance (dysbiosis) has been implicated in PCOS development. Understanding the gut-ovary axis offers new insights into PCOS pathophysiology and potential microbiome-based therapies.
Data Highlights
Clinical studies have identified reduced gut microbial diversity and specific taxonomic shifts in PCOS patients correlating with hyperandrogenism and insulin resistance. Animal models demonstrate that fecal microbiota transplantation from PCOS patients induces PCOS-like symptoms in healthy mice, supporting a causal role of gut dysbiosis.
Key Findings
PCOS patients exhibit gut microbiome dysbiosis characterized by decreased α-diversity and altered bacterial, fungal, and viral communities.
Gut microbial metabolites such as short-chain fatty acids, bile acids, and tryptophan derivatives modulate host metabolism and reproductive function.
Gut dysbiosis contributes to insulin resistance and hyperandrogenism, key pathological features of PCOS.
Fecal microbiota transplantation from PCOS patients to mice reproduces core disease manifestations, indicating a mechanistic role of microbiota.
Microbiome-targeted interventions including dietary modification, probiotics, prebiotics, and fecal transplantation show potential for precision medicine in PCOS.
Clinical Implications
Clinicians should consider the gut microbiome as a significant factor in PCOS pathogenesis and treatment. Incorporating microbiome-based therapies may improve metabolic and reproductive outcomes. Early intervention targeting gut dysbiosis could mitigate long-term complications associated with PCOS.
Conclusion
Gut microbiome dysbiosis plays a central role in PCOS pathogenesis through complex metabolic and endocrine interactions. Microbiome-targeted therapies represent a promising frontier for improving PCOS management and patient outcomes.
References
Rotterdam Criteria/Various -- Diagnostic criteria and prevalence of PCOS
Recent Reviews/Various -- Gut microbiome and PCOS pathogenesis
Animal Studies/Various -- Fecal microbiota transplantation and PCOS models
